Andrew D Miller

List of Publications by Year
in descending order

186	7,487	53794 45	64796 79
papers	citations	h-index	g-index

198	198	198	7650
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diphyllin Shows a Broad-Spectrum Antiviral Activity against Multiple Medically Important Enveloped RNA and DNA Viruses. Viruses, 2022, 14, 354.	3.3	8
2	Antiviral Activity of Vacuolar ATPase Blocker Diphyllin against SARS-CoV-2. Microorganisms, 2021, 9, 471.	3.6	14
3	Self-Assembled DNAâ€“PEG Bottlebrushes Enhance Antisense Activity and Pharmacokinetics of Oligonucleotides. ACS Applied Materials & Interfaces, 2020, 12, 45830-45837.	8.0	20
4	Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?. Viruses, 2020, 12, 998.	3.3	14
5	New opportunities for designing effective small interfering RNAs. Scientific Reports, 2019, 9, 16146.	3.3	3
6	Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines. Antiviral Research, 2019, 164, 23-51.	4.1	248
7	Diadenosine-Polyphosphate Analogue AppCH2ppA Suppresses Seizures by Enhancing Adenosine Signaling in the Cortex. Cerebral Cortex, 2019, 29, 3778-3795.	2.9	2
8	Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours. Journal of Controlled Release, 2018, 280, 87-98.	9.9	66
9	Hyaluronic Acid Surface Modified Liposomes Prepared via Orthogonal Aminoxy Coupling: Synthesis of Nontoxic Aminoxylipids Based on Symmetrically Ì±-Branched Fatty Acids, Preparation of Liposomes by Microfluidic Mixing, and Targeting to Cancer Cells Expressing CD44. Bioconjugate Chemistry, 2018, 29, 2343-2356.	3.6	25
10	Nonpyrogenic Molecular Adjuvants Based on norAbu-Muramyldipeptide and norAbu-Glucosaminyl Muramyldipeptide: Synthesis, Molecular Mechanisms of Action, and Biological Activities in Vitro and in Vivo. Journal of Medicinal Chemistry, 2017, 60, 7745-7763.	6.4	18
11	Multi-layered nanofibrous mucoadhesive films for buccal and sublingual administration of drug-delivery and vaccination nanoparticles - important step towards effective mucosal vaccines. Journal of Controlled Release, 2017, 249, 183-195.	9.9	96
12	Cationic lipid-based nanoparticles mediate functional delivery of acetate to tumor cells in vivo leading to significant anticancer effects. International Journal of Nanomedicine, 2017, Volume 12, 6677-6685.	6.7	16
13	The Position of His-Tag in Recombinant OspC and Application of Various Adjuvants Affects the Intensity and Quality of Specific Antibody Response after Immunization of Experimental Mice. PLoS ONE, 2016, 11, e0148497.	2.5	20
14	Stable, synthetic analogs of diadenosine tetraphosphate inhibit rat and human P2X3 receptors and inflammatory pain. Molecular Pain, 2016, 12, 174480691663770.	2.1	11
15	Precision active pharmaceutical ingredients are the goal. Future Medicinal Chemistry, 2016, 8, 1209-1238.	2.3	1
16	Evolving from academic to academic entrepreneur: overcoming barriers to scientific progress and finance. Future Medicinal Chemistry, 2016, 8, 1157-1162.	2.3	0
17	Nanomedicine therapeutics and diagnostics are the goal. Therapeutic Delivery, 2016, 7, 431-456.	2.2	5
18	Reprogramming of hepatic fat accumulation and 'browning' of adipose tissue by the short-chain fatty acid acetate. International Journal of Obesity, 2016, 40, 955-963.	3.4	171

#	Article	IF	Citations
19	Liposomal nanocarriers for plasminogen activators. Journal of Controlled Release, 2016, 227, 45-57.	9.9	56
20	The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism. Bioorganic and Medicinal Chemistry, 2016, 24, 1191-1203.	3.0	2
21	Antiviral activities of 2,6-diaminopurine-based acyclic nucleoside phosphonates against herpesviruses: In vitro study results with pseudorabies virus (PrV, SuHV-1). Veterinary Microbiology, 2016, 184, 84-93.	1.9	13
22	Lipid-Based Nanoparticles and Microbubbles â€“ Multifunctional Lipid-Based Biocompatible Particles for in vivo Imaging and Theranostics. , 2015, , .		6
23	Senseâ€“antisense (complementary) peptide interactions and the proteomic code; potential opportunities in biology and pharmaceutical science. Expert Opinion on Biological Therapy, 2015, 15, 245-267.	3.1	13
24	Thermosensitive, Near-Infrared-Labeled Nanoparticles for Topotecan Delivery to Tumors. Molecular Pharmaceutics, 2015, 12, 1335-1346.	4.6	25
25	Molecular Adjuvants Based on Nonpyrogenic Lipophilic Derivatives of norAbuMDP/GMDP Formulated in Nanoliposomes: Stimulation of Innate and Adaptive Immunity. Pharmaceutical Research, 2015, 32, 1186-1199.	3.5	20
26	Liposomal delivery systems for anti-cancer analogues of vitamin E. Journal of Controlled Release, 2015, 207, 59-69.	9.9	57
27	Delivering the promise of small ncRNA therapeutics. Therapeutic Delivery, 2014, 5, 569-589.	2.2	6
28	RNA Interference Therapeutics for Tumor Therapy. , 2014, , 393-408.		4
29	Syntheses of stable, synthetic diadenosine polyphosphate analogues using recombinant histidine-tagged lysyl tRNA synthetase (LysU). Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2346-2352.	2.2	6
30	Silencing the radicals improves Click Chemistry. Biotechnology Journal, 2014, 9, 595-596.	3.5	0
31	Biotin-c10-AppCH2ppA is an effective new chemical proteomics probe for diadenosine polyphosphate binding proteins. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2928-2933.	2.2	12
32	Nanomedicine in Cancer Diagnosis and Therapy: Converging Medical Technologies Impacting Healthcare. Nanostructure Science and Technology, 2014, , 365-384.	0.1	1
33	14: AUTO-ASSOCIATIVE LIPID-BASED SYSTEMS FOR NON-VIRAL NUCLEIC ACID DELIVERY. ICP Textbooks in Biomolecular Sciences, 2014, , 221-254.	0.1	4
34	Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA. Journal of Rnai and Gene Silencing, 2014, 10, 490-9.	1.2	13
35	Downâ€regulated lysosomal processing improved pegylated lipopolyplexâ€mediated gene transfection. Journal of Gene Medicine, 2013, 15, 182-192.	2.8	8
36	Examination of the effect of increasing the number of intra-disulfide amino functional groups on the performance of small molecule cyclic polyamine disulfide vectors. Journal of Controlled Release, 2013, 171, 81-90.	9.9	28

#	Article	IF	Citations
37	Delivery of RNAi therapeutics: work in progress. Expert Review of Medical Devices, 2013, 10, 781-811.	2.8	31
38	Assessing the preferred solution conformation of an interacting senseâ€“antisense (complementary) peptide pair. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 496-502.	2.2	4
39	Quantification of diadenosine polyphosphates in blood plasma using a tandem boronate affinityâ€“ion exchange chromatography system. Analytical Biochemistry, 2013, 432, 103-105.	2.4	4
40	Escherichia coli LysU is a potential surrogate for human lysyl tRNA synthetase in interactions with the C-terminal domain of HIV-1 capsid protein. Organic and Biomolecular Chemistry, 2013, 11, 612-620.	2.8	4
41	Multiple catalytic activities of <scp>E</scp>scherichiaÂcoli lysylâ€t<scp>RNA</scp> synthetase (<scp>L</scp>ys<scp>U</scp>) are dissected by siteâ€directed mutagenesis. FEBS Journal, 2013, 280, 102-114.	4.7	13
42	pH-Triggered Nanoparticle Mediated Delivery of siRNA to Liver Cells in Vitro and in Vivo. Bioconjugate Chemistry, 2013, 24, 314-332.	3.6	40
43	Effect of surface charge and ligand organization on the specific cell-uptake of uPAR-targeted nanoparticles. Journal of Drug Targeting, 2013, 21, 684-692.	4.4	16
44	Enzyme-Triggered PEGylated pDNA-Nanoparticles for Controlled Release of pDNA in Tumors. Bioconjugate Chemistry, 2013, 24, 343-362.	3.6	25
45	Lipid-Based Nanoparticles in Cancer Diagnosis and Therapy. Journal of Drug Delivery, 2013, 2013, 1-9.	2.5	68
46	The pH Sensitivity of Murine Heat Shock Protein 47 (HSP47) Binding to Collagen Is Affected by Mutations in the Breach Histidine Cluster. Journal of Biological Chemistry, 2013, 288, 4452-4461.	3.4	10
47	The statistical significance of selected senseâ€“antisense peptide interactions. Journal of Computational Chemistry, 2012, 33, 1440-1447.	3.3	5
48	Antiviral effect of HPMPC (CidofovirÂ®), entrapped in cationic liposomes: In vitro study on MDBK cell and BHV-1 virus. Journal of Controlled Release, 2012, 160, 330-338.	9.9	11
49	Enhancement of immune response towards non-lipidized Borrelia burgdorferi recombinant OspC antigen by binding onto the surface of metallochelating nanoliposomes with entrapped lipophilic derivatives of norÂbuMDP. Journal of Controlled Release, 2012, 160, 374-381.	9.9	22
50	Synthesis of novel PPARÎ±/Î³ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design programprotobuild. Organic and Biomolecular Chemistry, 2011, 9, 1169-1188.	2.8	20
51	Synthesis and Characterization of a Theranostic Vascular Disrupting Agent for In Vivo MR Imaging. Bioconjugate Chemistry, 2011, 22, 879-886.	3.6	23
52	Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. Journal of Controlled Release, 2011, 149, 111-116.	9.9	97
53	Metallochelating liposomes with associated lipophilised norAbuMDP as biocompatible platform for construction of vaccines with recombinant His-tagged antigens: Preparation, structural study and immune response towards rHsp90. Journal of Controlled Release, 2011, 151, 193-201.	9.9	49
54	Efficient topical delivery of plasmid DNA to lung in vivo mediated by putative triggered, PEGylated pDNA nanoparticles. Journal of Controlled Release, 2011, 154, 275-284.	9.9	30

#	Article	IF	Citations
55	Isolation and identification of diadenosine 5â€²,5â€´-P1,P4-tetraphosphate binding proteins using magnetic bio-panning. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7175-7179.	2.2	16
56	A Low Molecular Weight Folate Receptor Targeted Contrast Agent for Magnetic Resonance Tumor Imaging. Molecular Imaging and Biology, 2011, 13, 653-662.	2.6	27
57	Immobilization of histidine-tagged proteins on monodisperse metallochelation liposomes: Preparation and study of their structure. Analytical Biochemistry, 2011, 408, 95-104.	2.4	34
58	DNA and RNA delivery to the lungs using polymers. Journal of Drug Delivery Science and Technology, 2011, 21, 323-330.	3.0	1
59	Post-coupling strategy enables true receptor-targeted nanoparticles. Journal of Rnai and Gene Silencing, 2011, 7, 449-55.	1.2	3
60	Imaging of Gadolinium Spatial Distribution in Tumor Tissue by Laser Ablation Inductively Coupled Plasma Mass Spectrometry. Molecular Imaging and Biology, 2010, 12, 361-366.	2.6	33
61	DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. Journal of Controlled Release, 2010, 143, 222-232.	9.9	93
62	Novel phospholipid analogues of pan-PPAR activator tetradecylthioacetic acid are more PPARÎ± selective. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1252-1255.	2.2	8
63	Paramagnetic Liposome Nanoparticles for Cellular and Tumour Imaging. International Journal of Molecular Sciences, 2010, 11, 1759-1776.	4.1	73
64	Chemistry of Tumour Targeted T1 Based MRI Contrast Agents. Current Topics in Medicinal Chemistry, 2010, 10, 1158-1183.	2.1	22
65	Bioresponsive Small Molecule Polyamines as Noncytotoxic Alternative to Polyethylenimine. Molecular Pharmaceutics, 2010, 7, 2040-2055.	4.6	24
66	A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI. Organic and Biomolecular Chemistry, 2010, 8, 201-211.	2.8	45
67	The immunostimulatory effect of ILâ€1Î² in vivo is blocked by antisense peptides complementary to the loop sequence 163â€“171. FEBS Letters, 2009, 583, 792-796.	2.8	9
68	Controlling HBV Replication in Vivo by Intravenous Administration of Triggered PEGylated siRNA-Nanoparticles. Molecular Pharmaceutics, 2009, 6, 706-717.	4.6	112
69	Targeting the Urokinase Plasminogen Activator Receptor with Synthetic Self-Assembly Nanoparticles. Bioconjugate Chemistry, 2009, 20, 32-40.	3.6	53
70	Engineering and Optimization of Peptide-targeted Nanoparticles for DNA and RNA Delivery to Cancer Cells. IFMBE Proceedings, 2009, , 1503-1507.	0.3	2
71	Novel peptide ligand directs liposomes toward EGFâ€R highâ€expressing cancer cells in vitro and in vivo. FASEB Journal, 2009, 23, 1396-1404.	0.5	126
72	Synthesis and Analysis of Novel Glycerolipids for the Treatment of Metabolic Syndrome. Journal of Medicinal Chemistry, 2009, 52, 1172-1179.	6.4	10

#	Article	IF	Citations
73	Folate Receptor Targeted Bimodal Liposomes for Tumor Magnetic Resonance Imaging. Bioconjugate Chemistry, 2009, 20, 648-655.	3.6	126
74	Quantitative real-time PCR study on persistence of pDNA vaccine pVax-Hsp60 TM814 in beef muscles. Genetic Vaccines and Therapy, 2008, 6, 11.	1.5	12
75	Clostridium Neurotoxin Fragments as Potential Targeting Moieties for Liposomal Gene Delivery to the CNS. ChemBioChem, 2008, 9, 219-231.	2.6	32
76	Biophysical Properties of CDAN/DOPEâ€Analogue Lipoplexes Account for Enhanced Gene Delivery. ChemBioChem, 2008, 9, 455-463.	2.6	24
77	Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Therapy, 2008, 15, 1593-1605.	4.5	91
78	Bimodal Paramagnetic and Fluorescent Liposomes for Cellular and Tumor Magnetic Resonance Imaging. Bioconjugate Chemistry, 2008, 19, 118-129.	3.6	117
79	Towards Safe Nanoparticle Technologies for Nucleic Acid Therapeutics. Tumori, 2008, 94, 234-245.	1.1	15
80	Towards safe nanoparticle technologies for nucleic acid therapeutics. Tumori, 2008, 94, 234-45.	1.1	3
81	Hydrogel polymer appears to mimic the performance of the GroEL/GroES molecular chaperone machine. Organic and Biomolecular Chemistry, 2006, 4, 2568.	2.8	10
82	MAGfect: a novel liposome formulation for MRI labelling and visualization of cells. Organic and Biomolecular Chemistry, 2006, 4, 3489.	2.8	43
83	A dialkynoyl analogue of DOPE improves gene transfer of lower-charged, cationic lipoplexes. Organic and Biomolecular Chemistry, 2006, 4, 196-199.	2.8	40
84	The mechanism of GroEL/GroES folding/refolding of protein substrates revisited. Organic and Biomolecular Chemistry, 2006, 4, 1223.	2.8	10
85	Investigation into the Interactions between Diadenosine 5â€˝,5â€˝Ââ€˜â€˝-P1,P4-Tetraphosphate and Two Proteins:Â Molecular Chaperone GroEL and cAMP Receptor Proteinâ€. Biochemistry, 2006, 45, 3095-3106.	2.5	13
86	Liposomal preparations of muramyl glycopeptides as immunomodulators and adjuvants. Vaccine, 2006, 24, S90-S91.	3.8	11
87	The duality of LysU, a catalyst for both Ap4A and Ap3A formation. FEBS Journal, 2006, 273, 3534-3544.	4.7	23
88	In Vivo Studies of Dialkynoyl Analogues of DOTAP Demonstrate Improved Gene Transfer Efficiency of Cationic Liposomes in Mouse Lung. Journal of Medicinal Chemistry, 2006, 49, 349-357.	6.4	53
89	Effect of a non-hydrolyzable analog of diadenosine polyphosphates on NMDA-mediated currents in isolated pyramidal neurons of the rat hippocampus. Neurophysiology, 2006, 38, 169-174.	0.3	0
90	Novel fluorescent labelled affinity probes for diadenosine-5â€²,5â€´-P1,P4-tetraphosphate (Ap4A)-binding studies. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 943-948.	2.2	9

#	Article	IF	Citations
91	Identification and characterisation of human apoptosis inducing proteins using cell-based transfection microarrays and expression analysis. BMC Genomics, 2006, 7, 145.	2.8	42
92	Synthetic, Self-Assembly ABCD Nanoparticles; a Structural Paradigm for Viable Synthetic Non-Viral Vectors. ChemInform, 2006, 37, no.	0.0	1
93	A Novel Methodology for the Synthesis of Fumarates and Maleates. Synlett, 2006, 2006, 1933-1937.	1.8	0
94	Diadenosine Polyphosphate Analog Controls Postsynaptic Excitation in CA3-CA1 Synapses via a Nitric Oxide-Dependent Mechanism. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 579-588.	2.5	12
95	192. RGD- Functionalised Liposome for Tumour Targeting. Molecular Therapy, 2006, 13, S74-S75.	8.2	0
96	Stimulation of innate immunity in newborn kids againstCryptosporidium parvuminfection-challenge by intranasal/per-oral administration of liposomal formulation of N-L18-norAbu-GMDP adjuvant. Parasitology, 2005, 131, 601-608.	1.5	5
97	Site-directed genome modification: derivatives of DNA-modifying enzymes as targeting tools. Trends in Biotechnology, 2005, 23, 407-419.	9.3	43
98	Synthesis and Application of Integrin Targeting Lipopeptides in Targeted Gene Delivery. ChemBioChem, 2005, 6, 1212-1223.	2.6	25
99	The Facile Preparation of Primary and Secondary Amines via an Improved Fukuyamaâ€"Mitsunobu Procedure. Application to the Synthesis of a Lung-Targeted Gene Delivery Agent.. ChemInform, 2005, 36, no.	0.0	0
100	Molecular dynamics simulations of LysRS: An asymmetric state. Proteins: Structure, Function and Bioinformatics, 2005, 62, 649-662.	2.6	12
101	Observation of a 1,5-Silyl-Migration on Fructose. Synlett, 2005, 2005, 2385-2387.	1.8	4
102	Site-directed genome modification: nucleic acid and protein modules for targeted integration and gene correction. Trends in Biotechnology, 2005, 23, 399-406.	9.3	44
103	What Role Can Chemistry Play in Cationic Liposomeâ€Based Gene Therapy Research Today?. Advances in Genetics, 2005, 53PA, 69-118.	1.8	9
104	The facile preparation of primary and secondary amines via an improved Fukuyamaâ€"Mitsunobu procedure. Application to the synthesis of a lung-targeted gene delivery agent. Organic and Biomolecular Chemistry, 2005, 3, 1049-1057.	2.8	26
105	Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors. Chemical Society Reviews, 2005, 34, 970.	38.1	171
106	Intracellular Delivery of Nucleic Acids: Differences Between Transfection and siFection Reflect Differences Between DNA and RNA, and Between Oligodeoxynucleotides and Oligonucleotides. , 2005, , 441-455.		2
107	What role can chemistry play in cationic liposome-based gene therapy research today?. Advances in Genetics, 2005, 53, 71-118.	1.8	4
108	Nonviral Liposomes. , 2004, 90, 107-138.		6

#	Article	IF	Citations
109	Solid-Phase Assisted N-1 Functionalization of Azamacrocycles. Synlett, 2004, 2004, 453-456.	1.8	2
110	Gene Therapy Needs Robust Synthetic Nonviral Platform Technologies. ChemBioChem, 2004, 5, 53-54.	2.6	14
111	Gene Therapy Needs Robust Synthetic Nonviral Platform Technologies. ChemBioChem, 2004, 5, 256-256.	2.6	0
112	The facile solid-phase synthesis of cholesterol-based polyamine lipids. Tetrahedron Letters, 2004, 45, 3105-3107.	1.4	27
113	Synthesis of novel fluorescent-labelled dinucleoside polyphosphates. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2813-2816.	2.2	10
114	Facile Preparation of an Orthogonally Protected, pH-Sensitive, Bioconjugate Linker for Therapeutic Applications. Organic Letters, 2004, 6, 4245-4248.	4.6	15
115	Lipidic Carriers of siRNA:Â Differences in the Formulation, Cellular Uptake, and Delivery with Plasmid DNAâ€. Biochemistry, 2004, 43, 13348-13356.	2.5	329
116	De-novo design of complementary (antisense) peptide mini-receptor inhibitor of interleukin 18 (IL-18). Molecular Immunology, 2004, 41, 1217-1224.	2.2	17
117	Chemical Neuroimmunology: Health in a Nutshell Bidirectional Communication between Immune and Stress (Limbic-Hypothalamic-Pituitary-Adrenal) Systems. ChemBioChem, 2003, 4, 466-484.	2.6	17
118	Nuclear Localisation Sequence Templated Nonviral Gene Delivery Vectors: Investigation of Intracellular Trafficking Events of LMD and LD Vector Systems. ChemBioChem, 2003, 4, 286-298.	2.6	67
119	Quantitative single-step purification of dinucleoside polyphosphates. Analytical Biochemistry, 2003, 316, 135-138.	2.4	14
120	Evolutionary connection between the catalytic subunits of DNA-dependent RNA polymerases and eukaryotic RNA-dependent RNA polymerases and the origin of RNA polymerases. BMC Structural Biology, 2003, 3, 1.	2.3	218
121	Functional asymmetry in the lysyl-tRNA synthetase explored by molecular dynamics, free energy calculations and experiment. BMC Structural Biology, 2003, 3, 5.	2.3	22
122	Kinetic Study of DNA Condensation by Cationic Peptides Used in Nonviral Gene Therapy:â€‰ Analogy of DNA Condensation to Protein Folding. Biochemistry, 2003, 42, 10343-10347.	2.5	41
123	Thermodynamic Aspects and Biological Profile of CDAN/DOPE and DC-Chol/DOPE Lipoplexesâ€. Biochemistry, 2003, 42, 6067-6077.	2.5	46
124	Synthesis and Formulation of Neoglycolipids for the Functionalization of Liposomes and Lipoplexes. Bioconjugate Chemistry, 2003, 14, 884-898.	3.6	48
125	Comparison between the interactions of adenovirus-derived peptides with plasmid DNA and their role in gene delivery mediated by liposomeâ€“peptideâ€“DNA virus-like nanoparticles. Organic and Biomolecular Chemistry, 2003, 1, 2430-2438.	2.8	21
126	The Problem with Cationic Liposome / Micelle-Based Non-Viral Vector Systems for Gene Therapy. Current Medicinal Chemistry, 2003, 10, 1195-1211.	2.4	136

#	Article	IF	Citations
127	Unlocking Mechanisms in Gene Therapy, Stress and Proteomics. NATO Science Series Series II, Mathematics, Physics and Chemistry, 2003, , 297-316.	0.1	1
128	Isothermal Titration Calorimetry Reveals a Zinc Ion as an Atomic Switch in the Diadenosine Polyphosphates. Journal of Biological Chemistry, 2002, 277, 3073-3078.	3.4	19
129	Biophysical Characterization of the DNA Binding and Condensing Properties of Adenoviral Core Peptide Î¼ (mu). Biochemistry, 2002, 41, 652-659.	2.5	55
130	Order for Free: Molecular Diversity and Complexity Promote Self-Organisation. ChemBioChem, 2002, 3, 45-46.	2.6	8
131	Mechanistic Investigation into Complementary (Antisense) Peptide Mini-Receptor Inhibitors of Cytokine Interleukin-1. ChemBioChem, 2002, 3, 76-85.	2.6	19
132	Inhibition ofÎ²-Amyloid Aggregation and Neurotoxicity by Complementary (Antisense) Peptides. ChemBioChem, 2002, 3, 86-92.	2.6	19
133	Specific Interactions Between Sense and Complementary Peptides: The Basis for the Proteomic Code. ChemBioChem, 2002, 3, 136-151.	2.6	68
134	Specific Interactions Between Sense and Complementary Peptides: The Basis for the Proteomic Code. ChemBioChem, 2002, 3, 271-271.	2.6	1
135	Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide Î¼ (mu) and plasmid DNA. Gene Therapy, 2002, 9, 564-576.	4.5	88
136	A novel peptide, THALWHT, for the targeting of human airway epithelia. FEBS Letters, 2001, 489, 263-269.	2.8	44
137	Physico-chemical analysis of cationic liposomeâ€“DNA complexes (lipoplexes) with respect to in vitro and in vivo gene delivery efficiencyâ€. Perkin Transactions II RSC, 2001, , 624-632.	1.1	27
138	In vivo myocardial gene transfer: Optimization, evaluation and direct comparison of gene transfer vectors. Basic Research in Cardiology, 2001, 96, 227-236.	5.9	86
139	Access to the inaccessible sequence of Cpn 60.1 (195â€“217) by temporary oxazolidine protection of selected amide bonds. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 857-859.	2.2	19
140	Recent progress in the study of the intracellular functions of diadenosine polyphosphates. Drug Development Research, 2001, 52, 249-259.	2.9	34
141	Enhanced cationic liposome-mediated transfection using the DNA-binding peptide Î¼ (mu) from the adenovirus core. Gene Therapy, 2001, 8, 453-460.	4.5	78
142	The nuclear pore complex is involved in nuclear transfer of plasmid DNA condensed with an oligolysineâ€“RGD peptide containing nuclear localisation properties. Gene Therapy, 2001, 8, 1643-1653.	4.5	46
143	The Molecular Interactions of Heat Shock Protein 47 (Hsp47) and Their Implications for Collagen Biosynthesis. Journal of Biological Chemistry, 2001, 276, 49310-49319.	3.4	102
144	Synthesis of High-Mannose Type Neoglycolipids: Active Targeting of Liposomes to Macrophages in Gene Therapy. Chemistry - A European Journal, 2000, 6, 1416-1430.	3.3	45

#	Article	IF	Citations
145	Cell delivery, intracellular trafficking and expression of an integrin-mediated gene transfer vector in tracheal epithelial cells. Gene Therapy, 2000, 7, 139-152.	4.5	102
146	Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery. Gene Therapy, 2000, 7, 967-977.	4.5	67
147	Design of a Molecular Chaperone-Assisted Protein Folding Bioreactor. Biotechnology Progress, 2000, 16, 671-675.	2.6	17
148	The affinity of the GroEL/GroES complex for peptides under conditions of protein folding. FEBS Letters, 2000, 466, 75-79.	2.8	8
149	Cationic liposome-mediated DNA transfection in organotypic explant cultures of the ventral mesencephalon. Gene Therapy, 1999, 6, 190-197.	4.5	20
150	Molecular Chaperones Stimulate Bone Resorption. Calcified Tissue International, 1999, 64, 214-218.	3.1	22
151	Peptide Mini-Vectors for Gene Delivery. Angewandte Chemie - International Edition, 1999, 38, 1949-1952.	13.8	22
152	Characterisation of Cpn60 (GroEL) bound cytochrome c: the passive role of molecular chaperones in assisted folding/refolding of proteins. Journal of the Chemical Society Perkin Transactions II, 1999, , 1537.	0.9	6
153	A search within the IL-1 type I receptor reveals a peptide with hydropathic complementarity to the IL-1Î² trigger loop which binds to IL-1 and inhibits in vitro responses. Molecular Immunology, 1999, 36, 1141-1148.	2.2	20
154	Interaction with GroEL destabilises non-amphiphilic secondary structure in a peptide. FEBS Letters, 1999, 461, 131-135.	2.8	5
155	Secondary Structure Forming Propensity Coupled with Amphiphilicity Is an Optimal Motif in a Peptide or Protein for Association with Chaperonin 60 (GroEL)â€. Biochemistry, 1999, 38, 10272-10286.	2.5	25
156	Peptide Mini-Vectors for Gene Delivery. Angewandte Chemie - International Edition, 1999, 38, 1949-1952.	13.8	0
157	The Escherichia coli Chaperonin 60 (groEL) Is a Potent Stimulator of Osteoclast Formation. Journal of Bone and Mineral Research, 1998, 13, 1260-1266.	2.8	43
158	Î²-Galactosidase staining following intracoronary infusion of cationic liposomes in the in vivo rabbit heart is produced by microinfarction rather than effective gene transfer: a cautionary tale. Gene Therapy, 1998, 5, 301-308.	4.5	41
159	Endothelial cell transfection with cationic liposomes and herpes simplex-thymidine kinase mediated killing. Gene Therapy, 1998, 5, 614-620.	4.5	30
160	Enhanced in vitro and in vivo gene delivery using cationic agent complexed retrovirus vectors. Gene Therapy, 1998, 5, 1180-1186.	4.5	44
161	Liposomes enhance delivery and expression of an RGD-oligolysine gene transfer vector in human tracheal cells. Gene Therapy, 1998, 5, 1488-1498.	4.5	73
162	Polyamine Analogues of 3Î²-[N-(Nâ€²,Nâ€²-Dimethylaminoethane)carbamoyl]cholesterol (DC-Chol) as Agents for Gene Delivery. Chemistry - A European Journal, 1998, 4, 137-151.	3.3	110

#	Article	IF	Citations
163	Cationic Liposomes for Gene Therapy. Angewandte Chemie - International Edition, 1998, 37, 1768-1785.	13.8	420
164	An RGDâ€“Oligolysine Peptide: A Prototype Construct for Integrin-Mediated Gene Delivery. Human Gene Therapy, 1998, 9, 1037-1047.	2.7	184
165	The Expression of Constitutively Active Isotypes of Protein Kinase C to Investigate Preconditioning. Journal of Biological Chemistry, 1998, 273, 23072-23079.	3.4	88
166	Optimization of liposome mediated transfection of a neuronal cell line. NeuroReport, 1997, 8, 1481-1484.	1.2	29
167	Electrostatic as well as hydrophobic interactions are important for the association of Cpn60 (groEL) with peptides. Journal of the Chemical Society Perkin Transactions II, 1997, , 279-288.	0.9	18
168	Design of Antisense(Complementary) Peptides as Selective Inhibitors of Cytokine Interleukin-1. Angewandte Chemie International Edition in English, 1997, 36, 962-967.	4.4	23
169	Selektive Inhibierung von Interleukinâ€1 durch Antisenseâ€Peptide. Angewandte Chemie, 1997, 109, 999-1004.	2.0	4
170	Characterisation of stress protein LysU. Enzymic synthesis of diadenosine 5â€²,5â€´-P1,P4-tetraphosphate (Ap4A) analogues by LysU. Journal of the Chemical Society Perkin Transactions 1, 1996, , 2009-2019.	0.9	27
171	The crystal structure of the lysyl-tRNA synthetase (LysU) from Escherichia coli. Structure, 1995, 3, 163-176.	3.3	149
172	Modeling the Three-Dimensional Structure of Serpin/Molecular Chaperone HSP47. Bioorganic Chemistry, 1995, 23, 427-438.	4.1	14
173	Enhancement of Molecular Ion Intensity of Synthetic Analogs of Diadenosine 5â€²,5â€²â€²â€²-P1,P4-Tetraphosphate (Ap4A) in Negative-Ion Mode Fast Atom Bombardment Mass Spectrometry. Analytical Biochemistry, 1994, 218, 235-237.	2.4	3
174	Crystallization and Preliminary Diffraction Studies of Escherichia coli Lysyl-tRNA Synthetase (LysU). Journal of Molecular Biology, 1994, 243, 123-125.	4.2	17
175	Enzymatic synthesis of diadenosine 5â€², 5â€´-P1, P4-tetraphosphate (Ap4A) analogues by stress protein LysU. Journal of the Chemical Society Chemical Communications, 1994, .	2.0	18
176	Refolding and recognition of mitochondrial malate dehydrogenase by Escherichia coli chaperonins cpn 60 (groEL) and cpn10 (groES). Biochemical Journal, 1994, 302, 405-410.	3.7	30
177	Nonâ€“invasive liposomeâ€“mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nature Genetics, 1993, 5, 135-142.	21.4	425
178	Escherichia coli chaperonins cpn60 (groEL) and cpn10 (groES) do not catalyse the refolding of mitochondrial malate dehydrogenase. Biochemical Journal, 1993, 291, 139-144.	3.7	64
179	Biosynthesis of porphyrins and related macrocycles. Part 35. Discovery of a novel dipyrrolic cofactor essential for the catalytic action of hydroxymethylbilane synthase (porphobilinogen deaminase). Journal of the Chemical Society Perkin Transactions 1, 1990, , 1979.	0.9	11
180	Biosynthesis of the pigments of life: Structure and mode of action of a novel enzymatic cofactor. Bioorganic Chemistry, 1989, 17, 121-129.	4.1	8

#	Article	IF	Citations
181	Biosynthesis of porphyrins and related macrocycles. Part 34. Synthesis and properties of S-pyrrolylmethylcysteinyl and ÃŽÂµ-N-pyrrolylmethyllysyl peptides. Journal of the Chemical Society Perkin Transactions 1, 1989, , 1943-1956.	0.9	14
182	Evidence that pyridoxal phosphate modification of lysine residues (Lys-55 and Lys-59) causes inactivation of hydroxymethylbilane synthase (porphobilinogen deaminase). Biochemical Journal, 1989, 262, 119-124.	3.7	17
183	13C-N.M.R. Studies on the pyrromethane cofactor of hydroxymethylbilane synthase. Tetrahedron Letters, 1988, 29, 2591-2594.	1.4	26
184	Evidence that the pyrromethane cofactor of hydroxymethylbilane synthase (porphobilinogen) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 909-912.	3.7	53
185	Evidence that the pyrromethane cofactor of hydroxymethylbilane synthase (porphobilinogen) Tj ETQq1 1 0.784314 rgBT /Overlock 10 1988, 254, 915-918.	3.7	52
186	Biosynthesis of the natural porphyrins: proof that hydroxymethylbilane synthase (porphobilinogen) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Communications, 1987, , 1762.	2.0	64